Figures & data
Figure 1 US Food and Drug Administration-approved companion diagnostic drugs (2012).
Notes: *Other includes respiratory, systemic hormones, dermatologicals, alimentary tract and metabolism, nervous system, and various.
Table 1 US Food and Drug Administration Definition of Companion Diagnostic Drugs in Clinical Trials
Figure 2 Drugs with required pharmacogenetic companion diagnostic testing.
Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration.
Table 2 Comparison of development costs, patient enrollment, and time for non-small-cell lung cancer drugs
Figure 3 Companion diagnostic deals signed by year (A) and stage of companion diagnostic deal (B).
Figure 4 Annual value of financing for diagnostics and research tools companies (USD millions).
Notes: *Other includes debt, follow-on public offerings, private investments in public entities, initial public offerings, and spinoffs; excludes merger and acquisition transactions. Data above each bar refer to the total value of diagnostic and research tool financing for each year.
Abbreviations: USD, US dollars; VC, venture capital.
Abbreviations: USD, US dollars; VC, venture capital.
